Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
11 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
Novavax shares are trading higher Tuesday after U.S. FDA emergency use authorization for its updated 2026-2027 Nuvaxovid vaccine and an earlier Q2 update that raised full-year revenue guidance.
Ross Stores reported second-quarter revenue of $6.27 billion and earnings of $2.66 per share, both above estimates, and lifted 2026 earnings guidance to $8.61-$8.77 per share.
Target reports better-than-expected second-quarter earnings while Lowe’s posts mixed second-quarter 2026 results and narrows its full-year outlook below Wall Street estimates.
Lowe’s Companies shares rise after the retailer reported mixed second-quarter 2026 results, with adjusted EPS of $4.40 beating the $4.22 estimate while net sales of $25.96 billion missed $26.16 billion and full-year outlook narrowed below Wall Street estimates.
Target reported Q2 earnings of $2.46 per share versus the $2.33 analyst consensus estimate and sales of $26.539 billion versus $26.141 billion, then raised FY2026 adjusted EPS guidance and sales forecast.
US and Iran talks ongoing with all parties
Merck Q2 2026 Earnings
Quest Diagnostics (NYSE: DGX ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Quest Diagnos
() -- Healthcare stocks were declining premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.6% and the iShares Biotechnology ETF (IBB) 0.1% lower. Elevance Health (ELV) shares were down more than 8% after the company reported lower Q2 adjusted earnings. Johnson & Johnson (JNJ) stoc
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem